Research article
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
- Narrative review
Study context
- Population
- Patients with heart failure (HF) and new-onset cancer
Main finding
As reported in the abstract
Effects of guideline-directed HF pharmacotherapies, digoxin and diuretics on cancer (pre-clinical mechanisms; cancer incidence and cancer-related outcomes in observational studies and RCTs synthesised by meta-analyses)
- HF patients have a significantly higher risk of new-onset cancer and cancer-associated mortality than subjects free of HF
Original publication
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence. Eur Heart J. Published 5 March 2024. doi:10.1093/eurheartj/ehae105
Summarised from the published abstract; every number is checked against it